New horizons for selective 5-HT2C receptor ligands in psychiatric/neurological disorders.
Research, In Vivo Solutions, East Brunswick, NJ, USA. srlipson@gmail.com
Sharon
S
Rosenzweig-Lipson
D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects* / Q000235:genetics; D004195:Disease Models, Animal; D006801:Humans; D008024:Ligands; D051379:Mice; D019965:Neurocognitive Disorders / Q000188:drug therapy* / Q000378:metabolism* / Q000503:physiopathology; D044405:Receptor, Serotonin, 5-HT2C / Q000235:genetics / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D017366:Serotonin Receptor Agonists / Q000494:pharmacology / Q000627:therapeutic use
D008024:Ligands; D044405:Receptor, Serotonin, 5-HT2C; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists